Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

Revenue from Comirnaty, its COVID vaccine, has fallen by 66% this year. But in specialty care, revenue has risen by 11%, and in oncology, the company received a boost from drugs it acquired from ...

Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal issues. So let's examine this new green flag that's also a red flag for anyone ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Unlike at the height of the pandemic, oral antiviral therapy Paxlovid is Pfizer's strongest COVID-19 product now instead of its Comirnaty vaccine. In the third quarter of 2024, Paxlovid raked in sales ...

COMIRNATY Revenue: $1.4 billion. Non-COVID Products Revenue: $13.6 billion, reflecting 14% operational year-over-year growth. Adjusted Gross Margin: Approximately 72%. Total Adjusted Operating ...

Pfizer has reported strong revenues in its latest earnings report, noting increased revenues over Q3 2023 largely due to sales from the company’s Covid-19 drugs Paxlovid and Comirnaty. In the 29 ...